Skip to main content
Mui Van Zandt on Muck Rack

Mui Van Zandt

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mui

Contact Mui, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes

|
By Chungsoo Kim, Fan Bu, Clair Blacketer, Anna Ostropolets, Talita Duarte-Salles, Benjamin Viernes, Thomas Falconer, Andrea Pistillo, Jing Li, Can Yin, Mui Van Zandt, Paul Nagy, Akihiko Nishimura, Evan Minty, Seng Chan You, Mitsuaki Sawano, Shoko Sawano, Ja Young Jeon, Arya Aminorroaya, Lovedeep S Dhingra, Aline F Pedroso, Phyllis Thangaraj, David A. Dorr, Nicole Pratt, Kenneth K. C. Man, Wallis C. Y. Lau, Daniel Morales, Rohan Khera, Martijn J Schuemie, Patrick Ryan, George Hripcsak, Harlan M. Krumholz, Marc A. Suchard, Yuan Lu
| Nature Verified
Abstract As prescribing of newer antihyperglycemic agents expands, there remains limited comparative safety data for older adults—a population particularly vulnerable to adverse drug events and underrepresented in clinical trials. We conduct a multinational cohort study using nine databases from the U.S. and Europe. Among adults aged ≥65, we compare eighteen safety outcomes across four classes of second-line antihyperglycemic agents.
Open in Who Shared Issue with article?
See all 1 articles